Briacell Therap (NASDAQ:BCTX) Short Interest Down 84.4% in January

Briacell Therap (NASDAQ:BCTX) was the target of a large decline in short interest in January. As of January 15th, there was short interest totaling 43,910 shares, a decline of 84.4% from the December 31st total of 281,381 shares. Based on an average daily trading volume, of 1,355,400 shares, the short-interest ratio is presently 0.0 days. Currently, 2.5% of the company’s stock are sold short. Currently, 2.5% of the company’s stock are sold short. Based on an average daily trading volume, of 1,355,400 shares, the short-interest ratio is presently 0.0 days.

Briacell Therap Price Performance

Shares of NASDAQ:BCTX traded up $0.26 during midday trading on Tuesday, hitting $4.89. 2,549,202 shares of the company’s stock were exchanged, compared to its average volume of 882,700. Briacell Therap has a 12 month low of $4.10 and a 12 month high of $98.20. The company has a market cap of $9.19 million, a PE ratio of -0.11 and a beta of 1.38. The stock has a 50 day moving average price of $8.08 and a 200-day moving average price of $9.11.

Briacell Therap (NASDAQ:BCTX) last released its quarterly earnings results on Monday, December 15th. The company reported ($4.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($12.11) by $7.76. On average, analysts anticipate that Briacell Therap will post -2.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Briacell Therap

An institutional investor recently bought a new position in Briacell Therap stock. Citadel Advisors LLC acquired a new position in shares of Briacell Therap (NASDAQ:BCTX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned about 1.63% of Briacell Therap at the end of the most recent reporting period. Institutional investors own 15.42% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $320.00.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.